The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer Patients
Abstract
Adjuvant systemic therapy (a strategy that targets potential disseminated tumor cells after complete removal of the tumor) has clearly improved survival of patients with cancer. To date, no tool is available to monitor efficacy of these therapies, unless distant metastases arise, a situation that unavoidably leads to death. We analyzed RASSF1A DNA methylation in pretherapeutic sera and serum samples collected 1 year after surgery from 148 patients with breast cancer who were receiving adjuvant tamoxifen; 19.6% and 22.3% of patients with breast cancer showed RASSF1A DNA methylation in their pretherapeutic and 1-year-after serum samples, respectively. RASSF1A methylation 1 year after primary surgery (and during adjuvant tamoxifen therapy) was an independent predictor of poor outcome, with a relative risk (95% confidence interval) for relapse of 5.1 (1.3-19.8) and for death of 6.9 (1.9-25.9). Measurement of serum DNA methylation allows adjuvant systemic treatment to be monitored for efficacy: disappearance of RASSF1A DNA methylation in serum throughout treatment with tamoxifen indicates a response, whereas persistence or new appearance means resistance to adjuvant tamoxifen treatment. It remains to be seen whether modifications made in adjuvant therapeutic strategies based on detection of circulating nucleic acids will improve survival as well as quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Esteller, M., Sánchez‐Céspedes, M., Rosell, R., Sidransky, D., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 921
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
Widschwendter, M., Siegmund, K. D., Müller, H. M., Fiegl, H., Marth, C., Müller-Holzner, E., Jones, P. A., & Laird, P. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3852 · Cited by 324
Self-citationDNA methylation in serum of breast cancer patients: an independent prognostic marker.
Müller, H. M., Widschwendter, A., Fiegl, H., Ivarsson, L., Goebel, G., Perkmann, E., Marth, C., & Widschwendter, M. (2003) · PubMed · Cited by 317
Self-citationde Caceres, I. I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., & Cairns, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1529 · Cited by 282
Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.
Silva, J. M. R., Dominguez, G., Garcia, J. M., Gonzalez, R. M., Villanueva, M. J., Navarro, F., Provencio, M., Martin, S., España, P., & Bonilla, F. (1999) · PubMed · Cited by 236
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Circulating nucleic acids (CNAs) and cancer—A survey
Fleischhacker, M., & Schmidt, B. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.10.001 · Cited by 851
Ogino, S., Kawasaki, T., Brahmandam, M., Cantor, M., Kirkner, G. J., Spiegelman, D., Makrigiorgos, G. M., Weisenberger, D. J., Laird, P. W., Loda, M., et al. (2006) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050135 · Cited by 409
Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum
Umetani, N., Giuliano, A. E., Hiramatsu, S. H., Amersi, F., Nakagawa, T., Martino, S., & Hoon, D. S. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9493 · Cited by 351
Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature
Jung, K., Fleischhacker, M., & Rabien, A. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.032 · Cited by 337
Metadata
- Authors
- Fiegl, H., Millinger, S., Mueller-Holzner, E., Marth, C., Ensinger, C., Berger, A., Klocker, H., Goebel, G., & Widschwendter, M.
- Venue
- Cancer Research
- Published
- 2005-02-15
- Volume
- 65
- Issue
- 4
- Pages
- 1141-1145
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1985434928
- Cited by
- 252
- References
- 14
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-2438
- The paper
- Fiegl, H., Millinger, S., Mueller-Holzner, E., Marth, C., Ensinger, C., Berger, A., Klocker, H., Goebel, G., & Widschwendter, M. (2005). Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-2438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.